RepurpOS

Inflammatory Bowel Disease (Crohn's / UC)

Disease intelligence for Inflammatory Bowel Disease: 178 alterations and 200 ranked therapeutics from curated public databases.

US DALYs156.2KWHO GHE 2021 · all ages
Global DALYs1.29MWHO GHE 2021 · worldwide
US mortality1,512 deaths/yrWHO GHE 2021
Global mortality26.1K deaths/yrWHO GHE 2021 · worldwide
NIH funding$186MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionDisease course unchanged in ~85% of patients at 10 years on standard care; ~23% (CD) and ~12% (UC) relapse within 12…
Best-intervention remissionAnti-IL-23 biologics (mirikizumab, risankizumab) maintain steroid-free remission in >60% at 2 years — but on the drug…
Gap sizeLarge -- but between 'no remission' and 'on-drug remission'; drug-free remission remains rare
Primary barrierbiological
Full remission profile →

Disease overview

Alterations
178
Molecular (A)
100
Clinical (B–E)
78
Direct drugs
128
Via biomarker
72
Natural agents
0
Natural products
85
Merged ranked
200
With trial/literature evidence
25

Sources: Seeds, Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission
Disease course unchanged in ~85% of patients at 10 years on standard care; ~23% (CD) and ~12% (UC) relapse within 12 months of thiopurine withdrawal in sustained remission
Best-intervention remission
Anti-IL-23 biologics (mirikizumab, risankizumab) maintain steroid-free remission in >60% at 2 years — but on the drug, not drug-free
Drug-free remission
—
Relapse after remission
—
Chronicity
—
Gap size
Large -- but between 'no remission' and 'on-drug remission'; drug-free remission remains rare
Primary barrier
biological
Barrier detail: Biologic revolution has raised on-drug remission without meaningfully improving drug-free remission rates; true disease modification (cure-like durability off treatment) remains elusive

Last SoC change: 2023 — IL-23 inhibitors added to UC/CD ladder; 2018-2022 JAK inhibitors (tofacitinib, upadacitinib) added; anti-TNF (infliximab) first-line since 1998, essentially unchanged as backbone

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Related: Biomarker atlas · Intervention atlas

Identifiers: MONDO: MONDO:0005265 · EFO: EFO_0003764 · MESH: D015212 · UMLS_CUI: C0021398

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Inflammatory Bowel Disease may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.
Investigational Agents
115
Phase 3: 18, Phase 2: 63, Phase 1: 34
Most Advanced Phase
Phase 3
Highest dev. stage
Gene Targets
178
Actionable
Pipeline Compounds (Top 6)
Darapladib, Fenretinide, Adalimumab, Cholecalciferol, Iron Isomaltoside 1000, Vedolizumab
Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.
View Right-to-Try Compendium

Alterations

178 total · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
Abdominal pain Pathology Pathological finding — — Moderate HPO, Monarch HPO
Abnormal intestine morphology Pathology Pathological finding — — Moderate HPO, Monarch HPO
Anemia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Aphthous ulcer Pathology Pathological finding — — Moderate HPO, Monarch HPO
Atrophic gastritis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Blepharitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Bloody diarrhea Pathology Pathological finding — — Moderate HPO, Monarch HPO
Chapped lip Pathology Pathological finding — — Moderate HPO, Monarch HPO
Chronic diarrhea Pathology Pathological finding — — Moderate HPO, Monarch HPO
Chronic monilial nail infection Pathology Pathological finding — — Moderate HPO, Monarch HPO
Colitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Colorectal polyposis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Constipation Pathology Pathological finding — — Moderate HPO, Monarch HPO
Crohn's disease Pathology Pathological finding — — Moderate HPO, Monarch HPO
Diarrhea Pathology Pathological finding — — Moderate HPO, Monarch HPO
Duodenitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Early cutaneous photosensitivity Pathology Pathological finding — — Moderate HPO, Monarch HPO
Elevated circulating C-reactive protein concentration Lab / Clinical Lab value — — Moderate HPO, Monarch HPO
Elevated erythrocyte sedimentation rate Lab / Clinical Lab value — — Moderate HPO, Monarch HPO
Enterocolitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Enterocutaneous fistula Pathology Pathological finding — — Moderate HPO, Monarch HPO
Erythema Pathology Pathological finding — — Moderate HPO, Monarch HPO
Erythroderma Pathology Pathological finding — — Moderate HPO, Monarch HPO
Esophagitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Failure to thrive Pathology Pathological finding — — Moderate HPO, Monarch HPO
Folliculitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Gastritis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Generalized abnormality of skin Pathology Pathological finding — — Moderate HPO, Monarch HPO
Growth delay Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hematochezia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Horizontal eyebrow Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypertension Pathology Pathological finding — — Moderate HPO, Monarch HPO
Ileal stricture Pathology Pathological finding — — Moderate HPO, Monarch HPO
Ileitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Increased circulating IgE concentration Lab / Clinical Lab value — — Moderate HPO, Monarch HPO
Increased total leukocyte count Pathology Pathological finding — — Moderate HPO, Monarch HPO
Inflammation of the large intestine Pathology Pathological finding — — Moderate HPO, Monarch HPO
Intestinal fistula Pathology Pathological finding — — Moderate HPO, Monarch HPO
Intestinal obstruction Pathology Pathological finding — — Moderate HPO, Monarch HPO
Left ventricular hypertrophy Pathology Pathological finding — — Moderate HPO, Monarch HPO
Long eyelashes Pathology Pathological finding — — Moderate HPO, Monarch HPO
Motor delay Functional Functional — — Moderate HPO, Monarch HPO
Onychogryphosis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Oral ulcer Pathology Pathological finding — — Moderate HPO, Monarch HPO
Otitis externa Pathology Pathological finding — — Moderate HPO, Monarch HPO
Pancolitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Paronychia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Perianal abscess Pathology Pathological finding — — Moderate HPO, Monarch HPO
Perianal dermatitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Perianal erythema Pathology Pathological finding — — Moderate HPO, Monarch HPO
Perioral erythema Pathology Pathological finding — — Moderate HPO, Monarch HPO
Protein-losing enteropathy Pathology Pathological finding — — Moderate HPO, Monarch HPO
Psoriasiform dermatitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Pustule Pathology Pathological finding — — Moderate HPO, Monarch HPO
Pyoderma Pathology Pathological finding — — Moderate HPO, Monarch HPO
Rectovaginal fistula Pathology Pathological finding — — Moderate HPO, Monarch HPO
Recurrent aphthous stomatitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Recurrent bacterial skin infections Pathology Pathological finding — — Moderate HPO, Monarch HPO
Recurrent bronchitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Recurrent gastroenteritis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Scaling skin Pathology Pathological finding — — Moderate HPO, Monarch HPO
Secretory diarrhea Pathology Pathological finding — — Moderate HPO, Monarch HPO
Slow-growing scalp hair Pathology Pathological finding — — Moderate HPO, Monarch HPO
Ulcerative colitis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Villous atrophy Pathology Pathological finding — — Moderate HPO, Monarch HPO
Vomiting Pathology Pathological finding — — Moderate HPO, Monarch HPO
Weight loss Pathology Pathological finding — — Moderate HPO, Monarch HPO
ADAM17
ADAM metallopeptidase domain 17
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ADCY7
adenylate cyclase 7
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ALOX5
arachidonate 5-lipoxygenase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ALPI
alkaline phosphatase, intestinal
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ATG16L1
autophagy related 16 like 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Adverse Events During Reflux Esophagitis Maintenance Therapy Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
BACH2
BACH transcriptional regulator 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
BANK1
B cell scaffold protein with ankyrin repeats 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CARD8
caspase recruitment domain family member 8
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CARD9
caspase recruitment domain family member 9
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CCL20
C-C motif chemokine ligand 20
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CD40
CD40 molecule
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CD6
CD6 molecule
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CDKAL1
CDKAL1 threonylcarbamoyladenosine tRNA methylthiotransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CIITA
class II major histocompatibility complex transactivator
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CSF2RB
colony stimulating factor 2 receptor subunit beta
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CXCR2
C-X-C motif chemokine receptor 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Change in gut microbiota composition across study periods Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
DENND1B
DENN domain containing 1B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
DLD
dihydrolipoamide dehydrogenase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
EGFR
epidermal growth factor receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Efficacy: Total Mayo score (4 weeks comparison) Scales & PROs Clinical scale — — Emerging ClinicalTrials.gov —
FCGR2A
Fc gamma receptor IIa
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
FOSL2
FOS like 2, AP-1 transcription factor subunit
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
FUT2
fucosyltransferase 2 (H blood group)
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GALC
galactosylceramidase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GPR35
G protein-coupled receptor 35
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GPR65
G protein-coupled receptor 65
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
HSPA1L
heat shock protein family A (Hsp70) member 1 like
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Healthcare Resource: Number of Days of Hospitalization Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
IAH1
isoamyl acetate hydrolyzing esterase 1 (putative)
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IFIH1
interferon induced with helicase C domain 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IFNGR2
interferon gamma receptor 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL10
interleukin 10
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL10RA
interleukin 10 receptor subunit alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL10RB
interleukin 10 receptor subunit beta
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL12A
interleukin 12A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL12B
interleukin 12B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL18R1
interleukin 18 receptor 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL19
interleukin 19
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL21
interleukin 21
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL23A
interleukin 23 subunit alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL23R
interleukin 23 receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL2RA
interleukin 2 receptor subunit alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IL37
interleukin 37
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
INAVA
innate immunity activator
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IRF1
interferon regulatory factor 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IRF5
interferon regulatory factor 5
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IRGM
immunity related GTPase M
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ITGA4
integrin subunit alpha 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ITGB1
integrin subunit beta 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ITGB7
integrin subunit beta 7
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
JAK1
Janus kinase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
JAK2
Janus kinase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
JAK3
Janus kinase 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
JAZF1
JAZF zinc finger 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
LACC1
laccase domain containing 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MAP3K8
mitogen-activated protein kinase kinase kinase 8
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MMP9
matrix metallopeptidase 9
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MST1
macrophage stimulating 1
 Molecular Gene — — Emerging Open Targets Ensembl Open Targets
MUC19
mucin 19, oligomeric (gene/pseudogene)
 Molecular Gene — — Emerging Open Targets Ensembl Open Targets
NCF4
neutrophil cytosolic factor 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NFKB1
nuclear factor kappa B subunit 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NFKBIA
NFKB inhibitor alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NKX2-3
NK2 homeobox 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NOD2
nucleotide binding oligomerization domain containing 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NR3C1
nuclear receptor subfamily 3 group C member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NR5A2
nuclear receptor subfamily 5 group A member 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NXPE1
neurexophilin and PC-esterase domain family member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
OSMR
oncostatin M receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
OTUD3
OTU deubiquitinase 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PARK7
Parkinsonism associated deglycase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PDGFB
platelet derived growth factor subunit B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PLAU
plasminogen activator, urokinase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PLCG2
phospholipase C gamma 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PPARG
peroxisome proliferator activated receptor gamma
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PPAT
phosphoribosyl pyrophosphate amidotransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PRDM1
PR/SET domain 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PRKCB
protein kinase C beta
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTGS1
prostaglandin-endoperoxide synthase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTGS2
prostaglandin-endoperoxide synthase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTPN2
protein tyrosine phosphatase non-receptor type 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTPN22
protein tyrosine phosphatase non-receptor type 22
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Presence/Absence of Reflux Esophagitis Relapse Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
RIPK1
receptor interacting serine/threonine kinase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
RNF186
ring finger protein 186
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
RUNX3
RUNX family transcription factor 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
S1PR1
sphingosine-1-phosphate receptor 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
S1PR4
sphingosine-1-phosphate receptor 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
S1PR5
sphingosine-1-phosphate receptor 5
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SH2B3
SH2B adaptor protein 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC22A4
solute carrier family 22 member 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SMAD3
SMAD family member 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
STAT3
signal transducer and activator of transcription 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SYK
spleen associated tyrosine kinase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Safety Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
TAGAP
T cell activation RhoGTPase activating protein
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TET2
tet methylcytosine dioxygenase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TGFB1
transforming growth factor beta 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TNF
tumor necrosis factor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TNFAIP3
TNF alpha induced protein 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TNFSF15
TNF superfamily member 15
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TRIM22
tripartite motif containing 22
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TYK2
tyrosine kinase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
XIAP
X-linked inhibitor of apoptosis
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ZBTB38
zinc finger and BTB domain containing 38
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
mucosal drug concentration Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
vedolizumab drug concentration Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
İnflammatory markers Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug NameMechanismType
ACETAZOLAMIDE None Gene-targeted
ADALIMUMAB Gene-targeted
AMPHETAMINE None Gene-targeted
BALSALAZIDE Gene-targeted
BALSALAZIDE DISODIUM inhibitor Gene-targeted
BICALUTAMIDE None Gene-targeted
CARBACHOL None Gene-targeted
CIPROFLOXACIN None Gene-targeted
CLOMIPRAMINE None Gene-targeted
CURCUMIN Gene-targeted
DIAZEPAM None Gene-targeted
DICHLORPHENAMIDE None Gene-targeted
DIETHYLSTILBESTROL None Gene-targeted
EPIRUBICIN None Gene-targeted
ETANERCEPT Gene-targeted
ETHOXZOLAMIDE None Gene-targeted
FLUMAZENIL None Gene-targeted
IMIPRAMINE None Gene-targeted
INDAPAMIDE None Gene-targeted
INDOMETHACIN None Gene-targeted
INFLIXIMAB Gene-targeted
IRINOTECAN HYDROCHLORIDE Gene-targeted
ISOSORBIDE DINITRATE None Gene-targeted
MAFENIDE None Gene-targeted
MASOPROCOL Gene-targeted
MECAMYLAMINE None Gene-targeted
MECLOFENAMATE Gene-targeted
MECLOFENAMATE SODIUM inhibitor Gene-targeted
MESALAMINE inhibitor Gene-targeted
METHAZOLAMIDE None Gene-targeted
METHOTREXATE Gene-targeted
METHOXSALEN None Gene-targeted
METOPROLOL None Gene-targeted
MIANSERIN None Gene-targeted
MILK THISTLE SEED EXTRACT Gene-targeted
MONTELUKAST SODIUM Gene-targeted
NALIDIXIC ACID None Gene-targeted
NICOTINE None Gene-targeted
NORFLOXACIN None Gene-targeted
OFLOXACIN None Gene-targeted
OLSALAZINE SODIUM inhibitor Gene-targeted
PHENYTOIN None Gene-targeted
PRAZOSIN None Gene-targeted
SELENIUM Gene-targeted
SIROLIMUS None Gene-targeted
SULBACTAM None Gene-targeted
SULFASALAZINE inhibitor Gene-targeted
TACROLIMUS ANHYDROUS None Gene-targeted
TAZOBACTAM None Gene-targeted
TROGLITAZONE None Gene-targeted
ZILEUTON inhibitor; inhibitor Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ADALIMUMAB Repurposing Small molecule Approved Strong 95
8 trials 91 Cochrane 138 Meta-analysis 160 Trial pubs 104 RCT
View evidence

Registry trials

  • NCT00445939 — A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease (COMPLETED) PHASE2, PHASE3
  • NCT04131504 — Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) (COMPLETED)
  • NCT05720221 — Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients (COMPLETED)
  • NCT05530122 — Prognosis in UC After First Biological (COMPLETED)
  • NCT02852694 — Reduce Risk for Crohn's Disease Patients (COMPLETED) PHASE4
  • NCT01564823 — Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (COMPLETED) PHASE3
  • NCT02871635 — BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity (COMPLETED) PHASE3
  • NCT02413047 — Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (TERMINATED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
AMPHETAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
BALSALAZIDE Repurposing Small molecule Approved Strong 95
7 trials 7 Cochrane 5 Meta-analysis 17 Trial pubs 15 RCT
View evidence

Registry trials

  • NCT00618228 — Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions (COMPLETED) NA
  • NCT00269438 — New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3
  • NCT00408174 — Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT00486031 — Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study (COMPLETED) PHASE3
  • NCT04499495 — Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (COMPLETED)
  • NCT00618202 — A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
BALSALAZIDE DISODIUM Repurposing Small molecule Approved Strong 95
7 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT00618228 — Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions (COMPLETED) NA
  • NCT00269438 — New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3
  • NCT00408174 — Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT00486031 — Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study (COMPLETED) PHASE3
  • NCT04499495 — Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (COMPLETED)
  • NCT00618202 — A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CARBACHOL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CIPROFLOXACIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CURCUMIN Repurposing Small molecule Approved Strong 95
8 trials 15 Cochrane 13 Meta-analysis 17 Trial pubs 14 RCT
View evidence

Registry trials

  • NCT04713631 — Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease (UNKNOWN) PHASE2
  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT01647412 — Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease (WITHDRAWN) PHASE2
  • NCT05472753 — Dietary Supplement on the Intestinal Microbiota in Patients with Colon Cancer (COMPLETED) NA
  • NCT03500653 — Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab (UNKNOWN) NA
  • NCT07665294 — Combination CurQD and Vedolizumab in Ulcerative Colitis (NOT_YET_RECRUITING) PHASE4
  • NCT05761327 — Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis (COMPLETED) NA
  • NCT02683733 — Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis (UNKNOWN) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
DIAZEPAM Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ETANERCEPT Repurposing Small molecule Approved Strong 95
5 trials 6 Cochrane 10 Meta-analysis 6 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT03729674 — Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs (UNKNOWN)
  • NCT01860963 — Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls (COMPLETED) NA
  • NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2
  • NCT02376478 — On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection (COMPLETED)
  • NCT05702879 — Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success (UNKNOWN)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
ETHOXZOLAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
FLUMAZENIL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
IMIPRAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing Small molecule Approved Strong 95
2 trials 1 Trial pubs
View evidence

Registry trials

  • NCT00473980 — Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients (COMPLETED) PHASE4
  • NCT05999708 — A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants (WITHDRAWN) PHASE1

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INFLIXIMAB Repurposing Small molecule Approved Strong 95
8 trials 126 Cochrane 202 Meta-analysis 388 Trial pubs 198 RCT
View evidence

Registry trials

  • NCT00308581 — Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab (COMPLETED) PHASE3
  • NCT04344249 — Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic (COMPLETED)
  • NCT04131504 — Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) (COMPLETED)
  • NCT04761952 — N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease (UNKNOWN) NA
  • NCT00586599 — Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis (COMPLETED) NA
  • NCT06051253 — TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease (RECRUITING) PHASE4
  • NCT02177071 — A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy (COMPLETED) PHASE4
  • NCT05530122 — Prognosis in UC After First Biological (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
IRINOTECAN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT01588990 — A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (COMPLETED) PHASE4

CT.gov search · Cochrane · PubMed

 DGIdb —
ISOSORBIDE DINITRATE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MAFENIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MASOPROCOL Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MECLOFENAMATE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MECLOFENAMATE SODIUM Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
MESALAMINE Repurposing Small molecule Approved Strong 95
8 trials 47 Cochrane 54 Meta-analysis 152 Trial pubs 128 RCT
View evidence

Registry trials

  • NCT00245505 — The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease" (TERMINATED) PHASE3
  • NCT06213857 — Beneficial Effect of Silymarin in Ulcerative Colitis (RECRUITING) PHASE2
  • NCT01036022 — Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis (COMPLETED) PHASE2
  • NCT01016262 — Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis (TERMINATED) PHASE3
  • NCT00867438 — Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy (COMPLETED) PHASE2
  • NCT01004185 — Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis (TERMINATED) PHASE3
  • NCT03283085 — A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) (COMPLETED) PHASE3
  • NCT03327558 — Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects (COMPLETED) PHASE1

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
METHAZOLAMIDE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METHOTREXATE Repurposing Small molecule Approved Strong 95
8 trials 38 Cochrane 32 Meta-analysis 55 Trial pubs 35 RCT
View evidence

Registry trials

  • NCT02177071 — A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy (COMPLETED) PHASE4
  • NCT02852694 — Reduce Risk for Crohn's Disease Patients (COMPLETED) PHASE4
  • NCT02413047 — Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (TERMINATED) NA
  • NCT05386290 — A Multicentered Prospective Cohort Study of Chinese IBD Patients (UNKNOWN)
  • NCT03760003 — Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (COMPLETED) PHASE2
  • NCT01860963 — Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls (COMPLETED) NA
  • NCT01802593 — Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure (TERMINATED) PHASE4
  • NCT03553472 — Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
METHOXSALEN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METOPROLOL Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MILK THISTLE SEED EXTRACT Repurposing Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT06213857 — Beneficial Effect of Silymarin in Ulcerative Colitis (RECRUITING) PHASE2

CT.gov search · Cochrane · PubMed

 DGIdb —
MONTELUKAST SODIUM Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
NALIDIXIC ACID Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NICOTINE Repurposing Small molecule Approved Strong 95
4 trials 5 Cochrane 4 Meta-analysis 24 Trial pubs 16 RCT
View evidence

Registry trials

  • NCT02345733 — Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis (COMPLETED) PHASE4
  • NCT02922881 — Microbiota-targeted Diet for Pediatric UC (COMPLETED) NA
  • NCT00132899 — COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) (COMPLETED) PHASE3
  • NCT04653259 — Digital Nutrition Therapy for Patients With IBD (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing Small molecule Approved Strong 95
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
OLSALAZINE SODIUM Repurposing Small molecule Approved Strong 95
1 trials 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
PHENYTOIN Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
PRAZOSIN Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SELENIUM Repurposing Small molecule Approved Strong 95
5 trials 2 Cochrane 6 Trial pubs 6 RCT
View evidence

Registry trials

  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT06394544 — Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment (ACTIVE_NOT_RECRUITING) NA
  • NCT05472753 — Dietary Supplement on the Intestinal Microbiota in Patients with Colon Cancer (COMPLETED) NA
  • NCT07427017 — Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies (RECRUITING) PHASE2
  • NCT00793130 — The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
SIROLIMUS Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
SULBACTAM Repurposing Small molecule Approved Strong 95
1 Trial pubs 1 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SULFASALAZINE Repurposing Small molecule Approved Strong 95
6 trials 41 Cochrane 36 Meta-analysis 99 Trial pubs 68 RCT
View evidence

Registry trials

  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3
  • NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2
  • NCT02376478 — On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection (COMPLETED)
  • NCT06637683 — Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD) (COMPLETED) NA
  • NCT05458531 — Monitoring of Inflammatory Conditions (COMPLETED)
  • NCT04499495 — Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
TACROLIMUS ANHYDROUS Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT06749483 — The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units? (RECRUITING)

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TROGLITAZONE Repurposing Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ZILEUTON Repurposing Small molecule Approved Strong 95
2 Trial pubs 2 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
ADALIMUMAB Biologic Phase III Moderate 85 — Open Targets, ChEMBL ChEMBL Open Targets
CHOLECALCIFEROL Small molecule Phase III Moderate 85 — Open Targets, ChEMBL ChEMBL Open Targets
IRON ISOMALTOSIDE 1000 Small molecule Phase III Moderate 85 — Open Targets, ChEMBL ChEMBL Open Targets
VEDOLIZUMAB Biologic Phase III Moderate 85 — Open Targets, ChEMBL ChEMBL Open Targets
ANDROGRAPHOLIDE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
BALSALAZIDE DISODIUM Small molecule Phase III Moderate 80 — Open Targets, ChEMBL ChEMBL Open Targets
CHEMBL106 Small molecule Phase III Moderate 80 — ChEMBL ChEMBL Open Targets
CHEMBL2106049 Small molecule Phase III Moderate 80 — ChEMBL ChEMBL Open Targets
CHEMBL3833372 Small molecule Phase III Moderate 80 — ChEMBL ChEMBL Open Targets
CHEMBL3990014 Small molecule Phase III Moderate 80 — ChEMBL ChEMBL Open Targets
FERRIC CARBOXYMALTOSE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
FERRIC MALTOL Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
FERROUS FUMARATE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
INFLIXIMAB Biologic Phase III Moderate 80 — Open Targets, ChEMBL ChEMBL Open Targets
IRON SUCROSE Small molecule Phase III Moderate 80 — Open Targets ChEMBL Open Targets
USTEKINUMAB Biologic Phase III Moderate 80 — Open Targets, ChEMBL ChEMBL Open Targets
DARAPLADIB Repurposing Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
ETRASIMOD Small molecule Phase II Moderate 60 — Open Targets, ChEMBL ChEMBL Open Targets
FILGOTINIB Small molecule Phase II Moderate 60 — Open Targets, ChEMBL ChEMBL Open Targets
HYDROCORTISONE Small molecule Phase II Moderate 60 — Open Targets, ChEMBL ChEMBL Open Targets
MESALAMINE Small molecule Phase II Moderate 60 — Open Targets, ChEMBL ChEMBL Open Targets
PENTOXIFYLLINE Small molecule Phase II Moderate 60 — Open Targets, ChEMBL ChEMBL Open Targets
VIDOFLUDIMUS Small molecule Phase II Moderate 60 — Open Targets, ChEMBL ChEMBL Open Targets
BPC-157 Biologic Phase II Emerging 60 — Open Targets ChEMBL Open Targets
BUTYRIC ACID Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
CHEMBL121 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL1370 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL1431 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL1434 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL1487 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL1743068 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL244888 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL3707303 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL429910 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL629 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CHEMBL672 Small molecule Phase II Emerging 60 — ChEMBL ChEMBL Open Targets
CP-461 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DECLOPRAMIDE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DERSALAZINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DEXAMETHASONE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DORAMAPIMOD Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
DULOXETINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
FERROUS SULFATE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
FONTOLIZUMAB Biologic Phase II Emerging 60 — Open Targets ChEMBL Open Targets
GOLIMUMAB Biologic Phase II Emerging 60 — Open Targets ChEMBL Open Targets
ITX-5061 Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MIRTAZAPINE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MODAFINIL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
MONARSEN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NALTREXONE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NAVARIXIN Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
NAVARIXIN ANHYDROUS Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PREDNISOLONE SODIUM METAZOATE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
PRINABEREL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
RECOFLAVONE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
REMINERTANT Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
SEMAPIMOD Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
TAURURSODIOL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
TAZOFELONE Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
URSODIOL Small molecule Phase II Emerging 60 — Open Targets ChEMBL Open Targets
VATELIZUMAB Biologic Phase II Emerging 60 — Open Targets ChEMBL Open Targets
APRATASTAT Repurposing Small molecule Phase II Emerging 50 — DGIdb —
BMS-561392 Repurposing Small molecule Phase II Emerging 50 — DGIdb —
GSK3050002 Repurposing Small molecule Phase II Emerging 50 — DGIdb —
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN Repurposing Small molecule Phase II Emerging 50 — DGIdb —
ALPRENOLOL Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
2'-FUCOSYLLACTOSE Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
ALLOPURINOL Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
AMISELIMOD HYDROCHLORIDE Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
AZATHIOPRINE Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
ERGOCALCIFEROL Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
OCADUSERTIB Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
ROPSACITINIB Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
TAMUZIMOD Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
UDIFITIMOD Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
UDIFITIMOD HYDROCHLORIDE Small molecule Phase I Emerging 40 — Open Targets, ChEMBL ChEMBL Open Targets
CANNABIDIOL Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
CHEMBL1234886 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL2104398 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL2107830 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL2108326 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL2108939 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL2109606 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL4071864 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL4297973 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL4650343 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
CHEMBL64391 Small molecule Phase I Emerging 35 — ChEMBL ChEMBL Open Targets
FLIZASERTIB Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
GLEPAGLUTIDE Biologic Phase I Emerging 35 — Open Targets ChEMBL Open Targets
GSK-3179106 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
METHYLPREDNISOLONE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
NIACINAMIDE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
ORAZIPONE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
PF-07054894 Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
QUERCETIN Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
TILPISERTIB FOSMECARBIL Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
TOFACITINIB Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
VAMOROLONE Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
VANCOMYCIN Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
XYLITOL Small molecule Phase I Emerging 35 — Open Targets ChEMBL Open Targets
AMINOSALICYLIC ACID Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
AMOXICILLIN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ASCORBIC ACID Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
BALSALAZIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
BETAMETHASONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DOXYCYCLINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ELASOMERAN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
FERRIC OXYHYDROXIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
GUSELKUMAB Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
LACTULOSE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
MERCAPTOPURINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
METHOTREXATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
METRONIDAZOLE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
NABILONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PANTOTHENIC ACID Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
POLYETHYLENE GLYCOL Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
POLYETHYLENE GLYCOL 3350 Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
POTASSIUM CHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PREDNISOLONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PREDNISONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
PYRIDOXINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
ROPIVACAINE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SODIUM ASCORBATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SODIUM CHLORIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SODIUM PICOSULFATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SODIUM SULFATE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
SULESOMAB Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TAMTUVETMAB Biologic Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
THALIDOMIDE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TOZINAMERAN Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
TRIAMCINOLONE Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
UPADACITINIB Small molecule Preclinical Emerging 15 — Open Targets ChEMBL Open Targets
DrugTypePhaseEvidence ScoreSourcesLinks
ADALIMUMAB Biologic Phase III Moderate 85 Open Targets, ChEMBL ChEMBL Open Targets
CHOLECALCIFEROL Small molecule Phase III Moderate 85 Open Targets, ChEMBL ChEMBL Open Targets
IRON ISOMALTOSIDE 1000 Small molecule Phase III Moderate 85 Open Targets, ChEMBL ChEMBL Open Targets
VEDOLIZUMAB Biologic Phase III Moderate 85 Open Targets, ChEMBL ChEMBL Open Targets
ANDROGRAPHOLIDE Small molecule Phase III Moderate 80 Open Targets ChEMBL Open Targets
BALSALAZIDE DISODIUM Small molecule Phase III Moderate 80 Open Targets, ChEMBL ChEMBL Open Targets
CHEMBL106 Small molecule Phase III Moderate 80 ChEMBL ChEMBL Open Targets
CHEMBL2106049 Small molecule Phase III Moderate 80 ChEMBL ChEMBL Open Targets
CHEMBL3833372 Small molecule Phase III Moderate 80 ChEMBL ChEMBL Open Targets
CHEMBL3990014 Small molecule Phase III Moderate 80 ChEMBL ChEMBL Open Targets
FERRIC CARBOXYMALTOSE Small molecule Phase III Moderate 80 Open Targets ChEMBL Open Targets
FERRIC MALTOL Small molecule Phase III Moderate 80 Open Targets ChEMBL Open Targets
FERROUS FUMARATE Small molecule Phase III Moderate 80 Open Targets ChEMBL Open Targets
INFLIXIMAB Biologic Phase III Moderate 80 Open Targets, ChEMBL ChEMBL Open Targets
IRON SUCROSE Small molecule Phase III Moderate 80 Open Targets ChEMBL Open Targets
USTEKINUMAB Biologic Phase III Moderate 80 Open Targets, ChEMBL ChEMBL Open Targets
ETRASIMOD Small molecule Phase II Moderate 60 Open Targets, ChEMBL ChEMBL Open Targets
FILGOTINIB Small molecule Phase II Moderate 60 Open Targets, ChEMBL ChEMBL Open Targets
HYDROCORTISONE Small molecule Phase II Moderate 60 Open Targets, ChEMBL ChEMBL Open Targets
MESALAMINE Small molecule Phase II Moderate 60 Open Targets, ChEMBL ChEMBL Open Targets
PENTOXIFYLLINE Small molecule Phase II Moderate 60 Open Targets, ChEMBL ChEMBL Open Targets
VIDOFLUDIMUS Small molecule Phase II Moderate 60 Open Targets, ChEMBL ChEMBL Open Targets
BPC-157 Biologic Phase II Emerging 60 Open Targets ChEMBL Open Targets
BUTYRIC ACID Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
CHEMBL121 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL1370 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL1431 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL1434 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL1487 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL1743068 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL244888 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL3707303 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL429910 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL629 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CHEMBL672 Small molecule Phase II Emerging 60 ChEMBL ChEMBL Open Targets
CP-461 Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
DECLOPRAMIDE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
DERSALAZINE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
DEXAMETHASONE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
DORAMAPIMOD Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
DULOXETINE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
FERROUS SULFATE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
FONTOLIZUMAB Biologic Phase II Emerging 60 Open Targets ChEMBL Open Targets
GOLIMUMAB Biologic Phase II Emerging 60 Open Targets ChEMBL Open Targets
ITX-5061 Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
MIRTAZAPINE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
MODAFINIL Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
MONARSEN Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
NALTREXONE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
NAVARIXIN Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
NAVARIXIN ANHYDROUS Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
PREDNISOLONE SODIUM METAZOATE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
PRINABEREL Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
RECOFLAVONE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
REMINERTANT Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
SEMAPIMOD Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
TAURURSODIOL Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
TAZOFELONE Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
URSODIOL Small molecule Phase II Emerging 60 Open Targets ChEMBL Open Targets
VATELIZUMAB Biologic Phase II Emerging 60 Open Targets ChEMBL Open Targets
2'-FUCOSYLLACTOSE Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
ALLOPURINOL Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
AMISELIMOD HYDROCHLORIDE Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
AZATHIOPRINE Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
ERGOCALCIFEROL Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
OCADUSERTIB Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
ROPSACITINIB Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
TAMUZIMOD Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
UDIFITIMOD Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
UDIFITIMOD HYDROCHLORIDE Small molecule Phase I Emerging 40 Open Targets, ChEMBL ChEMBL Open Targets
CANNABIDIOL Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
CHEMBL1234886 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL2104398 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL2107830 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL2108326 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL2108939 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL2109606 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL4071864 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL4297973 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL4650343 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
CHEMBL64391 Small molecule Phase I Emerging 35 ChEMBL ChEMBL Open Targets
FLIZASERTIB Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
GLEPAGLUTIDE Biologic Phase I Emerging 35 Open Targets ChEMBL Open Targets
GSK-3179106 Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
METHYLPREDNISOLONE Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
NIACINAMIDE Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
ORAZIPONE Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
PF-07054894 Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
QUERCETIN Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
TILPISERTIB FOSMECARBIL Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
TOFACITINIB Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
VAMOROLONE Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
VANCOMYCIN Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
XYLITOL Small molecule Phase I Emerging 35 Open Targets ChEMBL Open Targets
AMINOSALICYLIC ACID Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
AMOXICILLIN Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
ASCORBIC ACID Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
BALSALAZIDE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
BETAMETHASONE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
DOXYCYCLINE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
ELASOMERAN Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
FERRIC OXYHYDROXIDE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
GUSELKUMAB Biologic Preclinical Emerging 15 Open Targets ChEMBL Open Targets
LACTULOSE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
MERCAPTOPURINE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
METHOTREXATE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
METRONIDAZOLE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
NABILONE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
PANTOTHENIC ACID Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
POLYETHYLENE GLYCOL Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
POLYETHYLENE GLYCOL 3350 Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
POTASSIUM CHLORIDE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
PREDNISOLONE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
PREDNISONE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
PYRIDOXINE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
ROPIVACAINE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
SODIUM ASCORBATE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
SODIUM CHLORIDE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
SODIUM PICOSULFATE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
SODIUM SULFATE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
SULESOMAB Biologic Preclinical Emerging 15 Open Targets ChEMBL Open Targets
TAMTUVETMAB Biologic Preclinical Emerging 15 Open Targets ChEMBL Open Targets
THALIDOMIDE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
TOZINAMERAN Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
TRIAMCINOLONE Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
UPADACITINIB Small molecule Preclinical Emerging 15 Open Targets ChEMBL Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ADALIMUMAB Repurposing via ATG16L1 Small molecule Approved Strong 95
8 trials 91 Cochrane 138 Meta-analysis 160 Trial pubs 104 RCT
View evidence

Registry trials

  • NCT00445939 — A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease (COMPLETED) PHASE2, PHASE3
  • NCT04131504 — Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) (COMPLETED)
  • NCT05720221 — Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients (COMPLETED)
  • NCT05530122 — Prognosis in UC After First Biological (COMPLETED)
  • NCT02852694 — Reduce Risk for Crohn's Disease Patients (COMPLETED) PHASE4
  • NCT01564823 — Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (COMPLETED) PHASE3
  • NCT02871635 — BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity (COMPLETED) PHASE3
  • NCT02413047 — Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (TERMINATED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
AMPHETAMINE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
BALSALAZIDE Repurposing via ALOX5 Small molecule Approved Strong 95
7 trials 7 Cochrane 5 Meta-analysis 17 Trial pubs 15 RCT
View evidence

Registry trials

  • NCT00618228 — Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions (COMPLETED) NA
  • NCT00269438 — New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3
  • NCT00408174 — Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT00486031 — Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study (COMPLETED) PHASE3
  • NCT04499495 — Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (COMPLETED)
  • NCT00618202 — A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
BALSALAZIDE DISODIUM Repurposing via ALOX5 Small molecule Approved Strong 95
7 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT00618228 — Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions (COMPLETED) NA
  • NCT00269438 — New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3
  • NCT00408174 — Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis (COMPLETED) PHASE3
  • NCT00486031 — Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study (COMPLETED) PHASE3
  • NCT04499495 — Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (COMPLETED)
  • NCT00618202 — A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
BICALUTAMIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CARBACHOL Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CIPROFLOXACIN Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
CURCUMIN Repurposing via ALPI Small molecule Approved Strong 95
8 trials 15 Cochrane 13 Meta-analysis 17 Trial pubs 14 RCT
View evidence

Registry trials

  • NCT04713631 — Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease (UNKNOWN) PHASE2
  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT01647412 — Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease (WITHDRAWN) PHASE2
  • NCT05472753 — Dietary Supplement on the Intestinal Microbiota in Patients with Colon Cancer (COMPLETED) NA
  • NCT03500653 — Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab (UNKNOWN) NA
  • NCT07665294 — Combination CurQD and Vedolizumab in Ulcerative Colitis (NOT_YET_RECRUITING) PHASE4
  • NCT05761327 — Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis (COMPLETED) NA
  • NCT02683733 — Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis (UNKNOWN) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
DIAZEPAM Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ETANERCEPT Repurposing via CARD8 Small molecule Approved Strong 95
5 trials 6 Cochrane 10 Meta-analysis 6 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT03729674 — Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs (UNKNOWN)
  • NCT01860963 — Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls (COMPLETED) NA
  • NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2
  • NCT02376478 — On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection (COMPLETED)
  • NCT05702879 — Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success (UNKNOWN)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
ETHOXZOLAMIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
FLUMAZENIL Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
IMIPRAMINE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing via ADAM17 Small molecule Approved Strong 95
2 trials 1 Trial pubs
View evidence

Registry trials

  • NCT00473980 — Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients (COMPLETED) PHASE4
  • NCT05999708 — A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants (WITHDRAWN) PHASE1

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INFLIXIMAB Repurposing via ADAM17 Small molecule Approved Strong 95
8 trials 126 Cochrane 202 Meta-analysis 388 Trial pubs 198 RCT
View evidence

Registry trials

  • NCT00308581 — Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab (COMPLETED) PHASE3
  • NCT04344249 — Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic (COMPLETED)
  • NCT04131504 — Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) (COMPLETED)
  • NCT04761952 — N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease (UNKNOWN) NA
  • NCT00586599 — Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis (COMPLETED) NA
  • NCT06051253 — TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease (RECRUITING) PHASE4
  • NCT02177071 — A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy (COMPLETED) PHASE4
  • NCT05530122 — Prognosis in UC After First Biological (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
IRINOTECAN HYDROCHLORIDE Repurposing via ALOX5 Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT01588990 — A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (COMPLETED) PHASE4

CT.gov search · Cochrane · PubMed

 DGIdb —
ISOSORBIDE DINITRATE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MAFENIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MASOPROCOL Repurposing via ALOX5 Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MECAMYLAMINE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MECLOFENAMATE Repurposing via ALOX5 Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MECLOFENAMATE SODIUM Repurposing via ALOX5 Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
MESALAMINE Repurposing via ALOX5 Small molecule Approved Strong 95
8 trials 47 Cochrane 54 Meta-analysis 152 Trial pubs 128 RCT
View evidence

Registry trials

  • NCT00245505 — The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease" (TERMINATED) PHASE3
  • NCT06213857 — Beneficial Effect of Silymarin in Ulcerative Colitis (RECRUITING) PHASE2
  • NCT01036022 — Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis (COMPLETED) PHASE2
  • NCT01016262 — Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis (TERMINATED) PHASE3
  • NCT00867438 — Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy (COMPLETED) PHASE2
  • NCT01004185 — Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis (TERMINATED) PHASE3
  • NCT03283085 — A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) (COMPLETED) PHASE3
  • NCT03327558 — Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects (COMPLETED) PHASE1

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
METHAZOLAMIDE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METHOTREXATE Repurposing via ALOX5 Small molecule Approved Strong 95
8 trials 38 Cochrane 32 Meta-analysis 55 Trial pubs 35 RCT
View evidence

Registry trials

  • NCT02177071 — A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy (COMPLETED) PHASE4
  • NCT02852694 — Reduce Risk for Crohn's Disease Patients (COMPLETED) PHASE4
  • NCT02413047 — Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (TERMINATED) NA
  • NCT05386290 — A Multicentered Prospective Cohort Study of Chinese IBD Patients (UNKNOWN)
  • NCT03760003 — Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (COMPLETED) PHASE2
  • NCT01860963 — Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls (COMPLETED) NA
  • NCT01802593 — Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure (TERMINATED) PHASE4
  • NCT03553472 — Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
METHOXSALEN Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
METOPROLOL Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
MILK THISTLE SEED EXTRACT Repurposing via ALOX5 Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT06213857 — Beneficial Effect of Silymarin in Ulcerative Colitis (RECRUITING) PHASE2

CT.gov search · Cochrane · PubMed

 DGIdb —
MONTELUKAST SODIUM Repurposing via ALOX5 Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
NALIDIXIC ACID Repurposing via ADAM17 Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NICOTINE Repurposing via ADAM17 Small molecule Approved Strong 95
4 trials 5 Cochrane 4 Meta-analysis 24 Trial pubs 16 RCT
View evidence

Registry trials

  • NCT02345733 — Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis (COMPLETED) PHASE4
  • NCT02922881 — Microbiota-targeted Diet for Pediatric UC (COMPLETED) NA
  • NCT00132899 — COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) (COMPLETED) PHASE3
  • NCT04653259 — Digital Nutrition Therapy for Patients With IBD (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing via ADAM17 Small molecule Approved Strong 95
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
OLSALAZINE SODIUM Repurposing via ALOX5 Small molecule Approved Strong 95
1 trials 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb ChEMBL Open Targets
PHENYTOIN Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
PRAZOSIN Repurposing via ADAM17 Small molecule Approved Strong 95
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SELENIUM Repurposing via ALOX5 Small molecule Approved Strong 95
5 trials 2 Cochrane 6 Trial pubs 6 RCT
View evidence

Registry trials

  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT06394544 — Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment (ACTIVE_NOT_RECRUITING) NA
  • NCT05472753 — Dietary Supplement on the Intestinal Microbiota in Patients with Colon Cancer (COMPLETED) NA
  • NCT07427017 — Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies (RECRUITING) PHASE2
  • NCT00793130 — The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
SIROLIMUS Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
SULBACTAM Repurposing via ADAM17 Small molecule Approved Strong 95
1 Trial pubs 1 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SULFASALAZINE Repurposing via ALOX5 Small molecule Approved Strong 95
6 trials 41 Cochrane 36 Meta-analysis 99 Trial pubs 68 RCT
View evidence

Registry trials

  • NCT01532648 — Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (COMPLETED) PHASE3
  • NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2
  • NCT02376478 — On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection (COMPLETED)
  • NCT06637683 — Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD) (COMPLETED) NA
  • NCT05458531 — Monitoring of Inflammatory Conditions (COMPLETED)
  • NCT04499495 — Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
TACROLIMUS ANHYDROUS Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing via ADAM17 Small molecule Approved Strong 95
1 trials
View evidence

Registry trials

  • NCT06749483 — The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units? (RECRUITING)

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TROGLITAZONE Repurposing via ADAM17 Small molecule Approved Strong 95 — ChEMBL ChEMBL Open Targets
ZILEUTON Repurposing via ALOX5 Small molecule Approved Strong 95
2 Trial pubs 2 RCT
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 DGIdb —
DARAPLADIB Repurposing via ADAM17 Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing via ADAM17 Small molecule Phase III Moderate 70 — ChEMBL ChEMBL Open Targets
APRATASTAT Repurposing via ADAM17 Small molecule Phase II Emerging 50 — DGIdb —
BMS-561392 Repurposing via ADAM17 Small molecule Phase II Emerging 50 — DGIdb —
GSK3050002 Repurposing via CCL20 Small molecule Phase II Emerging 50 — DGIdb —
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN Repurposing via CARD9 Small molecule Phase II Emerging 50 — DGIdb —
ALPRENOLOL Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ADAM17 Small molecule Phase II Emerging 45 — ChEMBL ChEMBL Open Targets

Natural Products

85 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Vitamin D3 Natural product Nutraceutical Approved Moderate 20
8 trials 21 Trial pubs 20 RCT
View evidence

Registry trials

  • NCT07656233 — Effect of Isoflavone and Vitamin D Supplementation on Serum Vitamin D Levels, Body Composition, Inflammatory Markers, and Quality of Life in Patients With Inflammatory Bowel Disease (COMPLETED) NA
  • NCT07241247 — Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy. (COMPLETED) PHASE4
  • NCT05649462 — Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis (COMPLETED)
  • NCT07593352 — Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD) (RECRUITING)
  • NCT03999580 — The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 ) (UNKNOWN) PHASE3
  • NCT02256605 — Vitamin D3 Supplementation in Pediatric IBD: Weely vs Daily Dosing Regimens (COMPLETED)
  • NCT02958501 — Vitamin D Substitution During Winter Time (UNKNOWN) PHASE4
  • NCT01718925 — 25-hydroxyvitamin D and Fatigue: The VITALITY Study (COMPLETED)

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Vitamin D3 Natural product Nutraceutical Approved Emerging 19
8 trials 21 Trial pubs 20 RCT
View evidence

Registry trials

  • NCT07656233 — Effect of Isoflavone and Vitamin D Supplementation on Serum Vitamin D Levels, Body Composition, Inflammatory Markers, and Quality of Life in Patients With Inflammatory Bowel Disease (COMPLETED) NA
  • NCT07241247 — Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy. (COMPLETED) PHASE4
  • NCT05649462 — Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis (COMPLETED)
  • NCT07593352 — Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD) (RECRUITING)
  • NCT03999580 — The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 ) (UNKNOWN) PHASE3
  • NCT02256605 — Vitamin D3 Supplementation in Pediatric IBD: Weely vs Daily Dosing Regimens (COMPLETED)
  • NCT02958501 — Vitamin D Substitution During Winter Time (UNKNOWN) PHASE4
  • NCT01718925 — 25-hydroxyvitamin D and Fatigue: The VITALITY Study (COMPLETED)

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov, Examine.com PubChem Examine.com
Omega-3 Fatty Acids Natural product Nutraceutical Approved Emerging 19
8 trials 5 Cochrane 9 Trial pubs
View evidence

Registry trials

  • NCT04147598 — Diet Study on Ulcerative Colitis (COMPLETED) NA
  • NCT02231203 — Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function (COMPLETED) PHASE4
  • NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease (RECRUITING) NA
  • NCT00074542 — An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease (COMPLETED) PHASE3
  • NCT07531342 — Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease (RECRUITING) NA
  • NCT02093780 — Personalized "Alberta" Diet for Prevention of Relapse in Ulcerative Colitis (COMPLETED) NA
  • NCT03594708 — Immunonutrition in Ulcerative Colitis (UNKNOWN) NA
  • NCT01575340 — Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Calcium Natural product Nutraceutical Approved Emerging 19
8 trials 9 Cochrane 43 Trial pubs
View evidence

Registry trials

  • NCT02984059 — Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease (COMPLETED)
  • NCT05171153 — Analysis of Bone Quality in Adult Patients With Inflammatory Bowel Disease (COMPLETED)
  • NCT01489943 — A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects (COMPLETED) PHASE1
  • NCT04276636 — Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency (UNKNOWN) EARLY_PHASE1
  • NCT03869905 — Aquamin® as an Adjuvant Intervention for Ulcerative Colitis (ACTIVE_NOT_RECRUITING) PHASE2
  • NCT03723447 — Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) (COMPLETED) PHASE4
  • NCT06538649 — Effect of Statins on Crohn's Disease (RECRUITING) EARLY_PHASE1
  • NCT02704624 — Effects of Supplementation of Vitamin D in Patients With Crohn's Disease (UNKNOWN) PHASE4

Published literature

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Curcumin Natural product Food compound Approved Moderate 17
8 trials 13 Meta-analysis
View evidence

Registry trials

  • NCT02683759 — Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis (UNKNOWN) PHASE3
  • NCT06867939 — A Study of Curcumin (Soloways ™) in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant (COMPLETED) NA
  • NCT07665294 — Combination CurQD and Vedolizumab in Ulcerative Colitis (NOT_YET_RECRUITING) PHASE4
  • NCT05761327 — Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis (COMPLETED) NA
  • NCT03500653 — Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab (UNKNOWN) NA
  • NCT02277223 — Curcumin in Pediatric Ulcerative Colitis (WITHDRAWN) PHASE3
  • NCT02683733 — Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis (UNKNOWN) PHASE3
  • NCT02255370 — Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease (COMPLETED) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Resveratrol Natural product Food compound Preclinical Moderate 17
3 trials 1 Meta-analysis 3 Trial pubs
View evidence

Registry trials

  • NCT05761327 — Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis (COMPLETED) NA
  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT07501377 — Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living With Overweight or Obesity (RECRUITING) NA

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Curcumin Natural product Food compound Approved Emerging 16
8 trials 13 Meta-analysis
View evidence

Registry trials

  • NCT02683759 — Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis (UNKNOWN) PHASE3
  • NCT06867939 — A Study of Curcumin (Soloways ™) in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant (COMPLETED) NA
  • NCT07665294 — Combination CurQD and Vedolizumab in Ulcerative Colitis (NOT_YET_RECRUITING) PHASE4
  • NCT05761327 — Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis (COMPLETED) NA
  • NCT03500653 — Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab (UNKNOWN) NA
  • NCT02277223 — Curcumin in Pediatric Ulcerative Colitis (WITHDRAWN) PHASE3
  • NCT02683733 — Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis (UNKNOWN) PHASE3
  • NCT02255370 — Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease (COMPLETED) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Resveratrol Natural product Food compound Phase II Emerging 16
3 trials 1 Meta-analysis 3 Trial pubs
View evidence

Registry trials

  • NCT05761327 — Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis (COMPLETED) NA
  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT07501377 — Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living With Overweight or Obesity (RECRUITING) NA

Published literature

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Probiotics Natural product Probiotic Phase III Emerging 16
8 trials 56 Trial pubs
View evidence

Registry trials

  • NCT00835874 — Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis (TERMINATED) NA
  • NCT01548014 — The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease (UNKNOWN) PHASE3
  • NCT02361957 — The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (SUSPENDED) NA
  • NCT00944736 — Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease (COMPLETED) PHASE3
  • NCT04136587 — The Bacterial Secretome in IBD (COMPLETED)
  • NCT01765439 — The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease (ACTIVE_NOT_RECRUITING) NA
  • NCT04305535 — Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease (UNKNOWN) NA
  • NCT03782428 — An Evaluation of Probiotic in the Clinical Course of Patients With Colorectal Cancer (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov —
Silymarin Natural product Botanical Phase II Emerging 13
2 trials
View evidence

Registry trials

  • NCT06213857 — Beneficial Effect of Silymarin in Ulcerative Colitis (RECRUITING) PHASE2
  • NCT04810572 — Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Ginger Natural product Botanical Phase I Emerging 10
3 trials
View evidence

Registry trials

  • NCT04340661 — Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients (TERMINATED) NA
  • NCT04879810 — Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (COMPLETED) NA
  • NCT04057547 — Efficacy and Safety of Modified Gegen Qinlian Decoction for Ulcerative Colitis With Damp-heat Syndrome (UNKNOWN) EARLY_PHASE1

CT.gov search · Cochrane · PubMed

 PubChem
Vitamin C Natural product Nutraceutical Approved Emerging 10
8 trials
View evidence

Registry trials

  • NCT03753425 — National Multicentric Observatory of Low Bowel Preparations in Patients With IBD (COMPLETED)
  • NCT04842149 — The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease (COMPLETED) NA
  • NCT02774057 — Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD (UNKNOWN) PHASE4
  • NCT04913467 — Effect of Ileocolonic Delivered Vitamins and an Anti-Inflammatory Diet on Crohn's Disease and Healthy Volunteers (UNKNOWN) NA
  • NCT00621257 — Vitamin D Levels in Children With IBD (TERMINATED) NA
  • NCT06382909 — Effect of Probiotic Compound K11T e K11TMax in ASD (COMPLETED) NA
  • NCT04513015 — Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (ACTIVE_NOT_RECRUITING) NA
  • NCT05726097 — Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure (COMPLETED) PHASE3

CT.gov search · Cochrane · PubMed

 PubChem
Omega-3 Fatty Acids Natural product Nutraceutical Approved Emerging 10
8 trials 5 Cochrane 9 Trial pubs
View evidence

Registry trials

  • NCT04147598 — Diet Study on Ulcerative Colitis (COMPLETED) NA
  • NCT02231203 — Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function (COMPLETED) PHASE4
  • NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease (RECRUITING) NA
  • NCT00074542 — An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease (COMPLETED) PHASE3
  • NCT07531342 — Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease (RECRUITING) NA
  • NCT02093780 — Personalized "Alberta" Diet for Prevention of Relapse in Ulcerative Colitis (COMPLETED) NA
  • NCT03594708 — Immunonutrition in Ulcerative Colitis (UNKNOWN) NA
  • NCT01575340 — Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Garlic Natural product Food compound Preclinical Emerging 10
1 trials
View evidence

Registry trials

  • NCT06541938 — AIRE-2 Device for Study of Breath Analysis in IBD (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 PubChem
Folate Natural product Nutraceutical Approved Emerging 10
8 trials
View evidence

Registry trials

  • NCT03860012 — Folic Acid in Pediatric Inflammatory Bowel Disease (UNKNOWN) PHASE4
  • NCT02376478 — On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection (COMPLETED)
  • NCT01393405 — Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (COMPLETED) PHASE2
  • NCT02774057 — Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD (UNKNOWN) PHASE4
  • NCT06059989 — InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease (RECRUITING) PHASE3
  • NCT01588990 — A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (COMPLETED) PHASE4
  • NCT02852694 — Reduce Risk for Crohn's Disease Patients (COMPLETED) PHASE4
  • NCT04160767 — Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients (UNKNOWN) PHASE4

CT.gov search · Cochrane · PubMed

 PubChem
Magnesium Natural product Nutraceutical Approved Emerging 10
8 trials 7 RCT
View evidence

Registry trials

  • NCT03753425 — National Multicentric Observatory of Low Bowel Preparations in Patients With IBD (COMPLETED)
  • NCT07338565 — Magnesium in Gastrointestinal Disease (RECRUITING)
  • NCT07593352 — Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD) (RECRUITING)
  • NCT05271838 — Protein and Magnesium in Ulcerative Colitis (UNKNOWN) NA
  • NCT04842149 — The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease (COMPLETED) NA
  • NCT02021253 — Influence of Probiotics Administration Before Liver Resection in Liver Disease (COMPLETED) NA
  • NCT06563349 — Magnesium Sulfate in Children Undergoing Laparoscopic Appendectomy (RECRUITING) PHASE4
  • NCT02000453 — Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis. (TERMINATED) PHASE1

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Butyrate Natural product Food compound Phase II Emerging 9
8 trials 7 Cochrane
View evidence

Registry trials

  • NCT04879914 — Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel Disease (COMPLETED) NA
  • NCT05456763 — Butyrate in Pediatric Inflammatory Bowel Disease (COMPLETED) NA
  • NCT06420492 — Study of Novel Therapeutics for Acute Remedy of Colitis (RECRUITING) PHASE2
  • NCT02217722 — Use of the Ulcerative Colitis Diet for Induction of Remission (TERMINATED) NA
  • NCT07591012 — Sodium Butyrate and Kluyveromyces Marxianus Supplementation in Inflammatory Bowel Disease (RECRUITING) NA
  • NCT06420375 — Treatment of UC With Novel Therapeutics (RECRUITING) PHASE2
  • NCT01282905 — Hydrogen Sulfide Detoxification and Butyrate Metabolism in Ulcerative Colitis (COMPLETED)
  • NCT04259060 — Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission (WITHDRAWN) PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Berberine Natural product Botanical Approved Emerging 7
3 trials
View evidence

Registry trials

  • NCT02365480 — Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission (COMPLETED) PHASE1
  • NCT04479202 — The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19 (COMPLETED) PHASE4
  • NCT02962245 — Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis (WITHDRAWN) PHASE4

CT.gov search · Cochrane · PubMed

 PubChem
Lactobacillus Natural product Probiotic Phase II Emerging 7
8 trials 14 Cochrane 13 Meta-analysis
View evidence

Registry trials

  • NCT00835874 — Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis (TERMINATED) NA
  • NCT00895336 — Lactobacillus GG in Pediatric Ulcerative Colitis (UC) (WITHDRAWN) PHASE2
  • NCT04305535 — Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease (UNKNOWN) NA
  • NCT03782428 — An Evaluation of Probiotic in the Clinical Course of Patients With Colorectal Cancer (COMPLETED) NA
  • NCT02021253 — Influence of Probiotics Administration Before Liver Resection in Liver Disease (COMPLETED) NA
  • NCT05118919 — A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis (COMPLETED) PHASE1, PHASE2
  • NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis (RECRUITING) NA
  • NCT03966846 — Kefir and Metabolic Syndrome (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 —
Andrographis Natural product Botanical Phase III Emerging 7
4 trials 2 RCT
View evidence

Registry trials

  • NCT00655733 — Phase II Study of HMPL-004 in Subjects With Crohn's Disease (COMPLETED) PHASE2
  • NCT01882764 — HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis (TERMINATED) PHASE3
  • NCT01805791 — A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis (TERMINATED) PHASE3
  • NCT00659802 — Phase II Study of HMPL-004 in Patients With Ulcerative Colitis (COMPLETED) PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Boswellia Natural product Botanical Preclinical Emerging 7 — PubChem
Spirulina Natural product Nutraceutical Preclinical Emerging 7 — —
Reishi Natural product Mushroom Preclinical Emerging 7 — —
Astragalus Natural product TCM herb Preclinical Emerging 7 — —
L-Carnitine Natural product Amino acid Preclinical Emerging 7 — PubChem
Coenzyme Q10 Natural product Nutraceutical Preclinical Emerging 7 — PubChem
Ginseng Natural product Botanical Preclinical Emerging 7 — —
Glucosamine Natural product Nutraceutical Preclinical Emerging 7 — PubChem
Multivitamin Natural product Nutraceutical Preclinical Emerging 7 — —
Cannabidiol Natural product Food compound Preclinical Emerging 2 — PubChem
Cts-1027 Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
(5R)-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Zileuton Natural product Food compound Preclinical Emerging 0 — ChEMBL ChEMBL PubChem ChEMBL
Indigo Naturalis Natural product Nutraceutical Preclinical Emerging 0 — —
Cannabis Natural product Nutraceutical Preclinical Emerging 0 — —
Flavonoids Natural product Nutraceutical Preclinical Emerging 0 — —
Aloe Vera Natural product Nutraceutical Preclinical Emerging 0 — —
Apple Polyphenols Natural product Nutraceutical Preclinical Emerging 0 — —
Chokeberry Natural product Nutraceutical Preclinical Emerging 0 — —
Cannabinoids Natural product Nutraceutical Preclinical Emerging 0 — —
Dandelion Natural product Nutraceutical Preclinical Emerging 0 — —
Goji Natural product Nutraceutical Preclinical Emerging 0 — —
Astragaloside Natural product Nutraceutical Preclinical Emerging 0 — —
EGCG (Epigallocatechin Gallate) Natural product Nutraceutical Preclinical Emerging 0 — —
Fiber Natural product Nutraceutical Preclinical Emerging 0 — —
Antioxidant Formulas Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Infantis Natural product Nutraceutical Preclinical Emerging 0 — —
Piperine Natural product Nutraceutical Preclinical Emerging 0 — —
Barley Grass Natural product Nutraceutical Preclinical Emerging 0 — —
Flaxseed Natural product Nutraceutical Preclinical Emerging 0 — —
Bifidobacterium Bifidum Natural product Nutraceutical Preclinical Emerging 0 — —
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 — —
Palmitoylethanolamide Natural product Nutraceutical Preclinical Emerging 0 — —
Potato Natural product Nutraceutical Preclinical Emerging 0 — —
Beta-Glucan Natural product Nutraceutical Preclinical Emerging 0 — —
Pomegranate Natural product Nutraceutical Preclinical Emerging 0 — —
Paeonol Natural product Nutraceutical Preclinical Emerging 0 — —
Bael Natural product Nutraceutical Preclinical Emerging 0 — —
Peony Natural product Nutraceutical Preclinical Emerging 0 — —
Apigenin Natural product Food compound Preclinical Emerging 0 — PubChem
Apples Natural product Nutraceutical Preclinical Emerging 0 — —
Artemisinin Natural product Nutraceutical Preclinical Emerging 0 — —
Baicalein Natural product Nutraceutical Preclinical Emerging 0 — —
Ginsenosides Natural product Nutraceutical Preclinical Emerging 0 — —
Catechin Natural product Nutraceutical Preclinical Emerging 0 — —
Lactobacillus Reuteri Natural product Nutraceutical Preclinical Emerging 0 — —
Anthocyanins Natural product Food compound Preclinical Emerging 0 — PubChem
Broccoli Natural product Nutraceutical Preclinical Emerging 0 — —
Bilberry Natural product Nutraceutical Preclinical Emerging 0 — —
Colostrum Natural product Nutraceutical Preclinical Emerging 0 — —
Fish Extract Natural product Nutraceutical Preclinical Emerging 0 — —
Fos (Fructooligosaccharides) Natural product Nutraceutical Preclinical Emerging 0 — —
Gum Arabic Natural product Nutraceutical Preclinical Emerging 0 — —
Coconut Water Natural product Nutraceutical Preclinical Emerging 0 — —
Kefir Natural product Nutraceutical Preclinical Emerging 0 — —
Lactoferrin Natural product Food compound Preclinical Emerging 0 — PubChem
Seal Oil Natural product Nutraceutical Preclinical Emerging 0 — —
Flaxseed Oil Natural product Nutraceutical Preclinical Emerging 0 — —
Delta-Tetrahydrocannabinol (THC) Natural product Nutraceutical Preclinical Emerging 0 — —
Yoghurt Natural product Nutraceutical Preclinical Emerging 0 — —

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.